Moreover, it has been shown that CIRT is able to upregulate in a dose-dependent manner the expression of PD-L1 both in cervical squamous and adenocarcinoma cell lines, inducing also a clinical PD-L1 expression in both the uterine histologies,52 paving the way to future combination with immunotherapy in these difficult-to-cure patients.53 Here, CD274 is linked to adenocarcinoma.